Obesity; Glp-1; Liver; Metabolic Health

* Dr. le Roux shares exclusive insights into the Phase 3 data for #Survodutide (Boehringer Ingelheim’s dual GLP-1/glucagon agonist), including its groundbreaking impact on visceral fat and #FattyLiverDisease (MASLD/MASH) via the SYNCHRONIZE trials. In this #DoctorPodcasts Episode 149, we...